Nanjing BioPoint® Diagnostic Technology Co. Ltd. (Nanjing BioPoint®) is an integrated Point of Care Testing (POCT) medical diagnostics company. It works in close collaboration with the world-renowned Burnet Institute in Melbourne, Australia, facilitating the efficient industrialization of Burnet's diagnostics R&D results into commercial products.
The mission of the Nanjing BioPoint® is to develop and commercialise POCT devices and assays in areas of UNMET MEDICAL NEED, to increase access to life-saving treatments for infectious diseases.
The first two products of the Nanjing BioPoint® are a POCT of the level of enzyme alanine aminotransferase1 (ALT1) in blood —BioPoint® ALT-1 and a plasma separation device VLPlasma®.
The products of Nanjing BioPoint® will provide simple, rapid and inexpensive diagnosis for those living in remote, resource poor countries and regions who do not have access to standard medical care and those living in advanced countries but for various reasons inconvenient to go to hospitals. These products are easy to use, remain effective for long time in room temperature, robust in transportation and do not require external electrical power to operate. Their use can reduce significantly the cost of providing health care and provide a solution for unmet medical need.